Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the group C protocol mechanism of the national cancer institute: A report of 979 patients

Journal of Clinical Oncology

Volumn 16, Issue 9, 1998, Pages 3007-3015

  Cheson, Bruce D ^a   Sorensen, J Mel ^b   Vena, Donald A ^b   Montello, Michael J ^b   Barrett, Jane A ^b   Damasio, Eugenio ^b   Tallman, Martin ^b   Annino, Luciana ^b   Connors, Joseph ^b   Coiffier, Bertrand ^b   Lauria, Francesco ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLADRIBINE; INTERFERON; PENTOSTATIN;

ADULT; AGED; ARTICLE; BLEEDING; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; HAIRY CELL LEUKEMIA; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SECOND CANCER; SKIN TOXICITY; VOMITING;

EID: 0031670669     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.9.3007     Document Type: Article

References (36)

1. Spiers ASD, Parekh SJ: Complete remission in hairy cell leukaemia achieved with pentostatin. Lancet 1:1080-1081, 1984
2. Kraut EH, Bouroncle BA, Grever MR: Low-dose deoxycoformycin in the treatment of hairy cell leukemia. Blood 68:1119-1122, 1986
3. Johnston JB, Glazer RI, Pugh L, et al: The treatment of hairy-cell leukaemia with 2′-deoxycoformycin. Br J Haematol 63:525-534, 1986
4. Spiers ASD, Moore D, Cassileth PA, et al: Remissions in hairy-cell leukemia with pentostatin (2′-deoxycoformycin). N Engl J Med 316:825-830, 1987
5. Cassileth PA, Cheuvart B, Spiers ASD, et al: Pentostatin induces durable remissions in hairy cell leukemia. J Clin Oncol 9:243-246, 1991
6. Grever M, Kopecky K, Foucar MK, et al: A randomized comparison of pentostatin vs alpha-interferon in previously untreated patients with hairy cell leukemia: An intergroup study. J Clin Oncol 13:974-982, 1995
7. Piro LD, Carrera CJ, Carson DA, et al: Lasting remissions in hairy cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med 322:1117-1121, 1990
8. Estey EH, Kurzrock R, Kantarjian HM, et al: Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA). Blood 79:882-887, 1992
9. Tallman M, Hakimian D, Variakojis D, et al: 2-Chlorodeoxyadenosine (2-CDA) in the treatment of hairy cell leukemia (HCL). Blood 78:34a, 1991 (suppl 1, abstr)
10. Lauria F, Benfenati D, Zinzani PL, et al: 2-Chlorodeoxyadenosine in the treatment of hairy cell leukemia patients relapsed after alpha-IFN. Blood 78:34a, 1991 (suppl 1, abstr 128)
11. Hoffman MA, Janson D, Rose E, et al: Treatment of hairy-cell leukemia with cladribine: Response, toxicity, and long-term follow-up. J Clin Oncol 15:1138-1142, 1997
12. Tallman MS, Hakimian D, Rademaker AW, et al: Relapse of hairy cell leukemia after 2-chlorodeoxyadenosine: Long-term follow-up of the Northwestern University experience. Blood 88:1954-1959, 1996
13. Mont ello M, Greenblatt JJ, Fallavollita A, et al: The NCI's Treatment Referral Center and non-research (compassionate) use of investigational agents. Am J Health Syst 55:651-660, 1998
14. MacDonald JS, Haller DG, Mayer RJ: Manual of Oncologic Therapeutics. Philadelphia, PA, JB Lippincott, 1995, pp 519-523
15. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
16. Hosmer DW, Lemeshow S: Applied Regression Analysis. New York, NY, Wiley, 1989
17. Cheson BD, Vena D, Foss F, et al: Neurotoxicity of purine analogs: A review. J Clin Oncol 12:2216-2228, 1994
18. + lymphocyte counts in patients with hairy cell leukemia. Blood 83:2906-2911, 1994
19. Ellison DJ, Sharpe RW, Robbins BA, et al: Immunomorphologic analysis of bone marrow biopsies after treatment with 2-chlorodeoxy-adenosine for hairy cell leukemia. Blood 84:4310-4315, 1994
20. Filleul B, Delannoy A, Ferrant A, et al: A single course of 2-chloro-deoxyadenosine does not eradicate leukemic cells in hairy cell leukemia patients in complete remission. Leukemia 8:1153-1156, 1994
21. Hakimian D, Tallman MS, Kiley C, et al: Detection of minimal residual disease by immunostaining of bone marrow biopsies after 2-chlorodeoxyadenosine for hairy cell leukemia. Blood 82:1798-1802, 1993
22. Wheaton S, Tallman MS, Hakimian D, et al: Minimal residual disease may predict bone marrow relapse in patients with hairy cell leukemia treated with 2-chlorodeoxyadenosine. Blood 87:1556-1560, 1996
23. Betticher DC, Fey MF, von Rohr A, et al: High incidence of infections after 2-chlorodeoxyadenosine (2-CDA) therapy in patients with malignant lymphomas and chronic and acute leukaemias. Ann Oncol 5:57-64, 1994
24. Cheson BD: Immunologic and immunosuppressive complications of purine analogue therapy. J Clin Oncol 13:2431-2448, 1995
25. Beutler E: Cladribine (2-chlorodeoxyadenosine). Lancet 340:952-956, 1992
26. Dann EJ, Gillis S, Polliack A, et al: Brief report: Tumor lysis syndrome following treatment with 2-chlorodeoxyadenosine for refractory chronic lymphocytic leukemia. N Engl J Med 329:1547-1548, 1993
27. Vahdat L, Wong ET, Wile MJ, et al: Therapeutic and neurotoxic effects of 2-chlorodeoxyadenosine in adults with acute myeloid leukemia. Blood 84:3429-3434, 1994
28. Spielberger RT, Larson RA, O'Brien SM, et al: Phase I study of 2-chlorodeoxyadenosine (CdA) by 1 hour bolus infusion in hematologic malignancies. Proc Am Soc Clin Oncol 12:140, 1993 (abstr 359)
29. Cheson BD, Vena D, Freidlin B, et al: The risk of secondary malignancies following purine analog therapy of chronic lymphocytic leukemia (CLL) and hairy cell leukemia (HCL). Proc Am Soc Clin Oncol 16:15a, 1997 (abstr 52)
30. Kurzrock R, Strom SS, Estey E, et al: Second cancer risk in hairy cell leukemia: Analysis of 350 patients. J Clin Oncol 15:1803-1810, 1997
31. Golomb HM, Ratain MJ, Mick R, et al: Interferon treatment for hairy cell leukemia: An update on a cohort of 69 patients treated from 1983-1986. Leukemia 6:1177-1180, 1992
32. Finn IW, Kopecky KJ, Foucar MK, et al: Long-term results in hairy cell leukemia (HCL) treated with pentostatin. Blood 90:578a, 1997 (suppl 1, abstr 2575)
33. Daeninck PJ, Johnston JB, Eisenhauer E, et al: Treatment of hairy cell leukemia with low-dose 2′deoxycoformycin: Results of long-term follow-up. Proc Am Soc Clin Oncol 16:17a, 1997 (abstr 60)
34. Frewin RJ, Provan D, Smith AG: Myelodysplasia occurring after fludarabine treatment for chronic lymphocytic leukemia. Clin Lab Haematol 19:151-152, 1997
35. Juliusson G, Heldal D, Hippe E, et al: Subcutaneous injections of 2-chlorodeoxyadenosine for symptomatic hairy cell leukemia. J Clin Oncol 13:989-995, 1995
36. Juliusson G, Christiansen I, Hansen MM, et al: Oral cladribine as primary therapy for patients with B-cell chronic lymphocytic leukemia. J Clin Oncol 14:2160-2166, 1996